Company Page
Most Recent Insiders Activity
| Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
|---|---|---|---|---|---|---|---|---|
| 2024-11-15 | Skye Bioscience, Inc. | Diep Tuan Tu
(Chief Development Officer) |
S | Common Stock | D | 19574 | $4.99 - $5.55 | $97,721 |
| 2024-11-15 | Skye Bioscience, Inc. | ARSENAULT KAITLYN
(Chief Financial Officer) |
S | Common Stock | D | 43396 | $4.99 - $5.55 | $216,651 |
| 2024-11-15 | Skye Bioscience, Inc. | DHILLON PUNIT
(Chief Executive Officer) |
S | Common Stock | D | 82910 | $4.99 - $5.55 | $413,924 |
| 2024-11-15 | Skye Bioscience, Inc. | Grayson Paul A.
(Director) |
S | Common Stock | D | 86551 | $4.99 - $5.55 | $432,060 |
| 2024-09-11 | Skye Bioscience, Inc. | Schwab Andrew J.
(Director) |
S | Common Stock | D | 266337 | $6.06 - $6.60 | $1,750,350 |
| 2024-09-11 | Skye Bioscience, Inc. | ROCKLAGE SCOTT M
(AtLeastTenPercentOwner) |
S | Common Stock | D | 266337 | $6.06 - $6.60 | $1,750,350 |
Activity types
| A | Grant, award or other acquisition |
| C | Conversion of Derivative or Security |
| D | Disposition to the issuer of issuer equity securities |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability |
| G | Bona fide Gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary Transaction |
| J | Other acquisition or disposition |
| K | Transaction in equity swap or instrument with similar characteristics |
| L | Small Acquisition |
| M | Exercise or conversion of derivative security |
| O | Exercise of out-of-the-money derivative security |
| P | Open Market Purchase |
| S | Open Market Sale |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| V | Transaction Voluntarily Reported |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |